Toll Free: 1-888-928-9744

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2017 in Pharmaceuticals

Published: Jul 10, 2017 | Pages: 73 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Partnerships, Licensing, Investments and M&A Deals and Trends for May 2017 in Pharmaceuticals

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for May 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in May 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported an increase in the number of deals and deal values in May 2017. The industry reported 373 deals worth USD37.8 billion in May 2017, compared to 307 deals worth USD21.5 billion in April 2017. The oncology therapeutics market remained at the top in deal activity in May 2017 with 126 deals. In second place, central nervous system therapeutics market reported 84 deals. Licensing agreements in pharmaceutical and healthcare industry registered a decrease in upfront payments. The segment reported USD199.7m as upfront payments in May 2017, compared to USD395.6m in 2017. The number of deals in North America increased to 229 in May 2017 from 192 in April 2017.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons To Buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
 Table of Contents
1 Table of Contents 2 1.1 List of Tables 5 1.2 List of Figures 6 2 Pharmaceuticals & Healthcare, Global, Deal Summary 8 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, May 2017 8 2.2 Pharmaceuticals & Healthcare, Global, Major Deals, May 2017 9 2.2.1 INC Research and inVentiv Health to Merge 9 2.2.2 Thermo Fisher Scientific to Acquire Patheon 11 2.2.3 Allergan Raises USD2.9 Billion in Public Offering of Notes 11 2.2.4 Becton Dickinson Raises USD2.47 Billion in Public Offering of Depositary Shares 12 2.2.5 Becton Dickinson Raises USD2.47 Billion in Public Offering of Shares 12 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, May 2017 13 2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, May 2017 14 3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 15 3.1 Pharmaceuticals & Healthcare, Global, M&A, May 2017 15 3.1.1 Top M&A Deals in May 2017 16 3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, December 2016- May 2017 16 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, May 2017 17 3.2.1 Top Equity Offering Deals in May 2017 18 3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, December 2016- May 2017 19 3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, May 2017 20 3.3.1 Top PE/VC Deals in May 2017 21 3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, May 2017 22 3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, May 2017 23 3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2016-May 2017 24 3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2016-May 2017 25 3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, May 2017 26 3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, December 2016- May 2017 27 3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), May 2017 28 3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, May 2017 29 3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), December 2016- May 2017 30 3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, December 2016- May 2017 31 3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), December 2016- May 2017 31 3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), December 2016- May 2017 33 4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, May 2017 35 4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, May 2017 35 4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2017 36 4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), December 2016- May 2017 37 4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), December 2016- May 2017 38 4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), December 2016- May 2017 39 4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), December 2016- May 2017 41 4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, May 2017 42 4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, May 2017 42 4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, May 2017 43 5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 44 5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, May 2017 44 5.1.1 Oncology - Deals of the Month 45 5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, May 2017 46 5.2.1 Central Nervous System - Deals of the Month 47 5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, May 2017 48 5.3.1 Infectious Diseases - Deals of the Month 49 5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, May 2017 50 5.4.1 Cardiovascular - Deal of the Month 51 5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, May 2017 52 5.5.1 Immunology - Deals of the Month 53 5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, May 2017 54 5.6.1 Gastrointestinal - Deal of the Month 55 5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, May 2017 56 5.7.1 Metabolic Disorders - Deal of the Month 57 6 Deal Summary by Geography 59 6.1 Pharmaceuticals & Healthcare, North America Deals, May 2017 59 6.1.1 North America - Deals of the Month 60 6.2 Pharmaceuticals & Healthcare, Europe, Deals, May 2017 61 6.2.1 Europe - Deals of the Month 62 6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, May 2017 63 6.3.1 Asia-Pacific - Deals of the Month 64 6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, May 2017 65 6.4.1 Rest of the World - Deals of the Month 66 7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 67 7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, December 2016- May 2017 67 7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, December 2016- May 2017 68 8 Further Information 69 8.1 Methodology 69 8.2 About GlobalData 70 8.3 Contact Us 70 8.4 Disclosure information 70 8.5 Disclaimer 71
List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 10 Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, May 2017 10 Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), May 2017 15 Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 16 Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, May 2017 17 Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2016- May 2017 18 Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 19 Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, May 2017 19 Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 20 Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 22 Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, May 2017 22 Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, December 2016- May 2017 23 Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), May 2017 25 Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), December 2016- May 2017 26 Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, December 2016- May 2017 26 Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), December 2016- May 2017 27 Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2016- May 2017 28 Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2016- May 2017 29 Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), May 2017 30 Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2016- May 2017 31 Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2016- May 2017 33 Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), December 2016- May 2017 35 Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 36 Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), December 2016- May 2017 37 Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2016- May 2017 38 Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), May 2017 39 Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2016- May 2017 41 Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2017 42 Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, May 2017 43 Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, May 2017 43 Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, May 2017 44 Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 46 Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 48 Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 50 Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 52 Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 54 Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 56 Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 58 Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 61 Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 63 Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 65 Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 66 Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), December 2016- May 2017 68 Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), December 2016- May 2017 69 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), December 2016- May 2017 10 Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), May 2017 15 Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), May 2017 16 Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), December 2016- May 2017 17 Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2016- May 2017 18 Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), December 2016- May 2017 19 Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2016- May 2017 21 Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), December 2016- May 2017 22 Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, December 2016- May 2017 24 Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), May 2017 25 Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), May 2017 25 Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), December 2016- May 2017 26 Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), December 2016- May 2017 28 Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2016- May 2017 29 Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2016- May 2017 30 Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2016- May 2017 32 Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2016- May 2017 33 Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, December 2016- May 2017 33 Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), December 2016- May 2017 35 Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), December 2016- May 2017 37 Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), December 2016- May 2017 38 Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), December 2016- May 2017 39 Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), December 2016- May 2017 40 Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, December 2016- May 2017 41 Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), December 2016- May 2017 41 Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), May 2017 43 Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), December 2016- May 2017 46 Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), December 2016- May 2017 48 Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), December 2016- May 2017 50 Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), December 2016- May 2017 52 Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), December 2016- May 2017 54 Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 56 Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), December 2016- May 2017 58 Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), December 2016- May 2017 61 Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), December 2016- May 2017 63 Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), December 2016- May 2017 65 Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), December 2016- May 2017 67 Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), December 2016- May 2017 69 Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), December 2016- May 2017 70



To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global coated fabrics market size forecast is estimated at USD 22.57 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing production of seat covers & airbags for automobile applications is likely to favor market growth.

Read More...

Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet o

Read More...

Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing i

Read More...

Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving cream

Read More...

Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the i

Read More...
Choose License Type
Single User - US $1000
Multi User - US $2000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify